Research To Practice | Oncology Videos

Latest Episodes:

Chronic Lymphocytic Leukemia | Paolo Ghia, MD, PhD May 03, 2025

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Chronic Lymphocytic Leukemia | Faculty Presentation 1: Current Role of Covalent Bruton Tyrosine Kinase Inhibitors and Bcl-2 Inhibitors in Chronic Lymphocytic Leukemia (CLL) — Paolo Ghia, MD, PhD

CME information and select publications

For Oncology Nurses: Ovarian Cancer — Proceedings from the 2025 Annual ONS Congress May 01, 2025

Show notes

Featuring perspectives from Ms Courtney Arn, Ms Jennifer Filipi, Dr David M O'Malley and Dr Shannon N Westin, including the following topics:

Introduction: Overview of Ovarian Cancer (OC) Management (0:00)
Genetic Testing for Newly Diagnosed Advanced OC (14:31)
Role of PARP Inhibitor Maintenance in Newly Diagnosed Advanced OC (22:46)
Other Available and Investigational Novel Strategies for OC (43:56)
Current and Future Role of Mirvetuximab Soravtansine in OC Treatment (1:19:24)

NCPD information and select publications

Prostate Cancer — Fourth Annual National General Medical Oncology Summit Apr 29, 2025

Show notes

Featuring perspectives from Dr Rahul Aggarwal and Dr William K Oh, including the following topics:

Hormonal Therapy for Patients with Prostate Cancer — Dr Oh (0:00)
Other Available and Emerging Therapeutic Approaches — Dr Aggarwal (27:14)

CME information and select publications

Immune Thrombocytopenia — A Roundtable Discussion on Current and Future Management Strategies Apr 29, 2025

Show notes

Featuring slide presentations and related discussion from Dr Hanny Al-Samkari, Dr James B Bussel and Prof Nichola Cooper, including the following topics:

Introduction (0:00)
Clinical Manifestations and Initial Management of Immune Thrombocytopenia (ITP) — Dr Al-Samkari (10:24)
Second- and Later-Line Therapies for ITP — Dr Bussel (1:00:51)
Tolerability and Other Practical Considerations with Available Treatment Strategies for Persistent/Chronic ITP — Prof Cooper (1:28:08)

CME information and select publications

Biliary Tract Cancers — Fourth Annual National General Medical Oncology Summit Apr 27, 2025

Show notes

Featuring perspectives from Dr Mitesh J Borad and Dr Amit Mahipal, including the following topics:

Introduction (0:00)
Targeted Therapeutic Approaches for Patients with Biliary Tract Cancers (BTCs) — Dr Mahipal (4:59)
Integration of Immune Checkpoint Inhibitors into Current BTC Management — Dr Borad (32:16)

CME information and select publications

For Oncology Nurses: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS Congress Apr 26, 2025

Show notes

Featuring perspectives from Ms Marianne J Davies, Dr Edward B Garon, Ms Marissa Marti-Smith and Dr Tiffany A Traina, including the following topics:

Introduction (0:00)
Overview of Antibody-Drug Conjugates (ADCs) (4:40)
Trastuzumab Deruxtecan (T-DXd) in Patients with HER2-Positive Metastatic Breast Cancer (mBC) with and without Brain Metastases (12:40)
Role of ADCs for Patients with ER-Positive mBC (35:09)
T-DXd in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) with HER2 Alterations (52:20)
Emerging Role of ADCs for Patients with Progressive EGFR-Mutant NSCLC (1:12:20)

NCPD information and select publications

Hormone Receptor-Positive Metastatic Breast Cancer — An Interview with Dr Adam M Brufsky on the Impact of Biomarkers and Existing Comorbidities on the Selection of First-Line Therapy Apr 25, 2025

Show notes

Featuring an interview with Dr Adam M Brufsky, including the following topics:

Case: A woman in her early 50s with ER-positive, HER2-low de novo metastatic breast cancer (0:00)
Case: A woman in her late 70s with ER-positive, HER2-low metastatic breast cancer after 5 years of an adjuvant aromatase inhibitor (6:52)
Clinical Investigator Survey Results (10:05)

CME information and select publications

Hormone Receptor-Positive Metastatic Breast Cancer — An Interview with Dr Adam M Brufsky on the Impact of Biomarkers and Existing Comorbidities on the Selection of First-Line Therapy (Companion Faculty Lecture) Apr 24, 2025

Show notes

Featuring a slide presentation and related discussion from Dr Adam M Brufsky, including the following topics:

Mechanism of action of and long-term data with CDK4/6 inhibitors in the management of metastatic breast cancer (mBC) (0:00)
Comparing safety profiles of CDK4/6 inhibitors (9:49)
Role of CDK4/6 inhibitors in therapy for older patients with mBC (24:06)
Real-world evidence with CDK4/6 inhibitors (27:31)

CME information and select publications

Genitourinary Cancers — An Interview with Dr William K Oh on Recent Trial Updates Apr 23, 2025

Show notes

Featuring an interview with Dr William K Oh, including the following topics:

Use of secondary hormonal agents for patients with metastatic hormone-sensitive prostate cancer (0:00)
Data supporting the clinical activity of PARP inhibitors for metastatic castration-resistant prostate cancer (mCRPC) (11:10)
Radiopharmaceuticals for the treatment of mCRPC (16:53)
Available data on cabozantinib for mCRPC (24:38)
Cabozantinib combinations for advanced renal cell carcinoma (RCC) (26:17)
Subcutaneous nivolumab versus intravenous nivolumab for advanced RCC (30:00)
Addition of nivolumab to tivozanib compared to tivozanib alone in advanced relapsed/refractory RCC previously treated with an immune checkpoint inhibitor (31:28)
Long-term follow-up with belzutifan for relapsed/refractory advanced RCC (33:39)
Major findings from the NIAGARA study of perioperative durvalumab for muscle-invasive bladder cancer (MIBC) (35:44)
Data surrounding adjuvant immunotherapy for MIBC (38:07)
Clinical development of TAR-200 for high-risk non-muscle-invasive bladder cancer (39:44)
Updated analysis of EV-302 study of enfortumab vedotin in combination with pembrolizumab for previously untreated advanced urothelial cancer (UC) (41:06)
Implementation of emerging data in the treatment landscape of UC (41:56)

CME information and select publications

Relapsed/Refractory Follicular Lymphoma Part 1 — A Roundtable Discussion on the Selection and Sequencing of Bispecific Antibodies Apr 22, 2025

Show notes

Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics:

Overview of Bispecific Antibodies for the Treatment of Relapsed/Refractory (R/R) Follicular Lymphoma (FL) (0:00)
Clinical Data Available with Mosunetuzumab for R/R FL (1:54)
Clinical Data Available with Epcoritamab for R/R FL (4:54)
Clinical Data Available with Odronextamab for R/R FL (6:53)
Clinical Considerations in Selecting Among Available Bispecific Antibodies for R/R FL (8:34)
Practical Considerations in the Administration of Bispecific Antibodies (15:21)
The Role of Vaccinations in the Prevention of Infections for Patients Receiving Bispecific Antibodies (18:34)
Ongoing Clinical Trials Evaluating Bispecific Antibodies for FL (21:34)
Case: A man in his late 60s with refractory FL who received mosunetuzumab monotherapy (24:24)
Case: A woman in her late 50s with relapsed FL who received third-line epcoritamab monotherapy (30:14)
Case: A man in his late 80s with a long-standing history of FL who received odronextamab in combination with a second novel bispecific antibody (33:48)

CME information and select publications

Our TOPPODCAST Picks

Follow Us

Stay Connected

Research To Practice | Oncology Videos

Related Podcasts

Links

Stay Connected